No sentence-transformers model found with name cambridgeltl/SapBERT-from-PubMedBERT-fulltext. Creating a new one with mean pooling.
Initializing Qdrant client...
✓ Qdrant client initialized
Loading embedding models...
✓ SapBERT loaded
✓ multilingual-e5 loaded
✓ All models loaded

1. Qdrant検索実行...
   ✓ 言語検出: ja
   ✓ 論文数: 5
2. Atomic Facts検索実行...
   ✓ アトミックファクト数: 5
3. MedGemma生成実行...

検索された論文詳細:

論文 1:
  PMID: PMID_39476339
  Title: Once-Weekly Semaglutide in Persons with Obesity and Knee Osteoarthritis.
  Journal: The New England journal of medicine (2024)
  Score: 0.9322923025570471
  PICO Patient: Adults with obesity (BMI ≥30) and a clinical and radiologic diagnosis of moderate knee osteoarthritis with at least moderate pain. Mean age 56 years, mean BMI 40.3, mean WOMAC pain score 70.9. 81.6% women.
  PICO Intervention: Once-weekly subcutaneous semaglutide (2.4 mg) in addition to counseling on physical activity and a reduced-calorie diet for 68 weeks.
  PICO Outcome: Percentage change in body weight from baseline to week 68: -13.7% with semaglutide vs. -3.2% with placebo (P<0.001). Change in WOMAC pain score from baseline to week 68: -41.7 points with semaglutide vs. -27.5 points with placebo (P<0.001). Change in SF-36 physical-function score: 12.0 points with semaglutide vs. 6.5 points with placebo (P<0.001).

論文 2:
  PMID: PMID_40499738
  Title: Glucagon-Like Peptide-1 Receptor Agonists and Gastrointestinal Adverse Events: A Systematic Review and Meta-Analysis.
  Journal: Gastroenterology (2025)
  Score: 0.8263175605693331
  PICO Patient: Patients with type 2 diabetes mellitus, overweight/obesity, or metabolic dysfunction-associated steatohepatitis/metabolic dysfunction-associated steatotic liver disease.
  PICO Intervention: Glucagon-like peptide-1 receptor agonists (GLP-1RAs). Specific dosing, duration, and formulation details were evaluated in subgroup analyses but not specified for the overall meta-analysis.
  PICO Outcome: Increased risk of cholelithiasis (Risk Ratio [RR], 1.46; 95% CI, 1.09-1.97; 2 more cases per 1000) and probable increased risk of GERD (RR, 2.19; 95% CI, 1.48-3.25; 4 more cases per 1000) compared with placebo.

論文 3:
  PMID: PMID_39305981
  Title: Seven glucagon-like peptide-1 receptor agonists and polyagonists for weight loss in patients with obesity or overweight: an updated systematic review and network meta-analysis of randomized controlled trials.
  Journal: Metabolism: clinical and experimental (2024)
  Score: 0.818107981878991
  PICO Patient: Patients with obesity or overweight. Patients without type 2 diabetes mellitus (T2DM) and patients with type 2 diabetes mellitus (T2DM). Patients with high body mass index (BMI) and patients with low BMI.
  PICO Intervention: Seven GLP-1 receptor agonists and polyagonists: mazdutide (6 or 4.5 mg), retatrutide (12 or 8 mg), tirzepatide (15 or 10 mg), liraglutide (3.0 mg), semaglutide (2.4 mg), orforglipron (45 or 36 mg), and beinaglutide (0.2 mg). Intervention duration of at least 16 weeks.
  PICO Outcome: Percentage change in body weight from baseline. Retatrutide 12 mg: -22.10% (CI not provided, p-value not provided). Retatrutide 8 mg: -20.70% (CI not provided, p-value not provided). Tirzepatide 15 mg: -16.53% (CI not provided, p-value not provided).

論文 4:
  PMID: PMID_39719170
  Title: Effect of glucagon-like peptide-1 receptor agonists and co-agonists on body composition: Systematic review and network meta-analysis.
  Journal: Metabolism: clinical and experimental (2025)
  Score: 0.8170889746065011
  PICO Patient: Adults with diabetes and/or overweight/obesity
  PICO Intervention: Glucagon-like peptide-1 receptor agonists (GLP-1RAs) and GLP-1/GIP receptor dual agonists (GLP-1/GIP-RAs)
  PICO Outcome: Total body weight reduction (MD -3.55 kg, 95%-CI [-4.81, -2.29]), fat mass reduction (MD -2.95 kg, 95%-CI [-4.11, -1.79]), and lean mass reduction (MD -0.86 kg, 95%-CI [-1.30, -0.42])

論文 5:
  PMID: PMID_39841962
  Title: Efficacy of GLP-1 Receptor Agonists on Weight Loss, BMI, and Waist Circumference for Patients With Obesity or Overweight: A Systematic Review, Meta-analysis, and Meta-regression of 47 Randomized Controlled Trials.
  Journal: Diabetes care (2025)
  Score: 0.8166400601516975
  PICO Patient: Adults with obesity or overweight, with or without diabetes.
  PICO Intervention: Glucagon-like peptide 1 receptor agonists (GLP-1 RAs). Specific dosage and duration not detailed in abstract.
  PICO Outcome: Mean weight reduction of -4.57 kg (95% CI -5.35 to -3.78), mean BMI reduction of -2.07 kg/m2 (95% CI -2.53 to -1.62), and mean waist circumference reduction of -4.55 cm (95% CI -5.72 to -3.38) compared with placebo.

アトミックファクト (5 件):
  2. Dual or triple receptor agonists are more effective for weight loss than GLP-1 receptor agonists.
  3. Dual or triple receptor agonists are more effective for weight loss than GLP-1 receptor agonists.
  4. Glucagon-like peptide-1 receptor agonists (GLP-1RAs) were assessed in patients with type 2 diabetes mellitus, overweight/obesity, or metabolic dysfunction-associated steatohepatitis/metabolic dysfunction-associated steatotic liver disease.
  5. GLP-1RAs increased the risk of cholelithiasis compared to placebo (RR, 1.46; 95% CI, 1.09-1.97).
  6. Retatrutide (both doses) and tirzepatide exhibited superior efficacy compared to other GLP-1 receptor agonists and polyagonists in reducing body weight and waist circumference.

======================================================================
✓ Mode: qdrant_augmented
✓ Query: glp1受容体作動薬は変形性膝関節症に有効ですか?
✓ Time: 26149.7ms

Answer:
glp1受容体作動薬は変形性膝関節症に有効ですか?
はい、glp1受容体作動薬は変形性膝関節症に有効である可能性が示唆されています。
Paper 1では、肥満のある変形性膝関節症の患者において、once-weekly semaglutideが体重減少、痛み、機能障害の改善に有効であることが示されました。
Paper 3では、retatrutide（12 mg）とtirzepatide（15 mg）が、他のglp1受容体作動薬やpolyagonistsと比較して、体重減少と腰囲の減少においてsuperior efficacyを示しました。
これらの論文は、glp1受容体作動薬が変形性膝関節症の症状を改善する可能性を支持しています。
ただし、これらの研究は肥満のある患者を対象としており、変形性膝関節症の患者全体に対する有効性はまだ十分に確立されていません。
また、glp1受容体作動薬は、胆石症などの副作用のリスクも高める可能性があります。
最終的な判断は、医師と相談して行う必要があります。
(重要な注意点: この回答は教育目的であり、医療アドバイスではありません。必ず専門家にご相談ください。)

======================================================================
Exception ignored in: <function QdrantClient.__del__ at 0x1084734c0>
Traceback (most recent call last):
  File "/Users/g150446/.pyenv/versions/3.11.6/lib/python3.11/site-packages/qdrant_client/qdrant_client.py", line 169, in __del__
  File "/Users/g150446/.pyenv/versions/3.11.6/lib/python3.11/site-packages/qdrant_client/qdrant_client.py", line 178, in close
  File "/Users/g150446/.pyenv/versions/3.11.6/lib/python3.11/site-packages/qdrant_client/local/qdrant_local.py", line 85, in close
ImportError: sys.meta_path is None, Python is likely shutting down
